

BIOGRAPHICAL SKETCH

NAME Karyn M. Warsow	POSITION TITLE Clinical Research Scientist/Regulatory Compliance Auditor
--------------------------------	------------------------------------------------------------------------------------

INSTITUTION AND LOCATION	DEGREE	YEAR CONFERRED	FIELD OF STUDY
Wayne State University Detroit, Michigan	BA	1991	English
Wayne State University Detroit, Michigan	BS	1991	Psychology
Wayne State University, School of Medicine Detroit, Michigan	MS	1997	Basic Medical Sciences
University of Illinois at Chicago, School of Public Health	MPH	2003	Community Health Science
Johns Hopkins, Bloomberg School of Public Health	DrPH Student	Present	Health Policy Management and Leadership/Research

Professional Experience:

2007-Present *Clinical Research Scientist/Regulatory Compliance Auditor (Business Owner), The Marrickar Group, LLC, Gaylord, Michigan*

- Wayne State University School of Medicine, Department of Pulmonary Critical Care & Sleep Medicine, Detroit, Michigan (T32 Training Grant Development/Writing/Submission)
- The Road Information Program (TRIP), Washington DC (Safety Analysis Research/Writing)
- Continental 1 Trade Corridor, Buffalo, New York (Safety Analysis Client/Research Consultation)
- City of Gaylord/Otsego County Road Commission (TIGER Grant Development/Writing/Submission)

2007-2008 *Research Associate, Trauma Administration, Division of General Surgery, Akron General Medical Center, Trauma Level I, Akron, Ohio*

2005-2006 *Clinical Research Consultant/Study Manager/Monitor, DePuy Orthopaedics, Inc. (Aerotek Scientific, Contractor), Clinical Research, Division of Trauma and Extremities, Warsaw, Indiana*

2004-2005 *Pharmacokinetics Operations Associate/Project Management, Lilly Research Laboratories (Voll Scientific, Contractor), Drug Disposition: Global Pharmacokinetics/Pharmacodynamic/Trial Simulation, Oncology, Indianapolis, Indiana*

Employment from 1985-2003 was on limited grant funded projects to attain a tuition waive (worked full-time and attended school full-time)

2001- 2002 *Project Director, Nursing Case Management in the Prevention of Sexually Transmitted Disease for At-Risk African American Women (NIH Grant Funded), Public Health, Mental Health and Administrative Nursing, College of Nursing, University of Illinois at Chicago, Chicago, Illinois.*

1999-2000 *Clinical Research and Grants Administrator, Faculty Staff, Instructor of Medicine, Department of Medicine, Pulmonary Critical Care, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.*

Detroit Medical Center

1998-1999 *Clinical Research Coordinator, DMC Asthma Care Program (NIH Grant funded), Department of Internal Medicine, Pulmonary Critical Care, Detroit Receiving Hospital/Wayne State University, School of Medicine, Detroit, Michigan.*

- 1992-1997 *Clinical Research Coordinator*, Department of Surgery, Detroit Receiving Hospital/Wayne State University, School of Medicine, Detroit, Michigan.
- 1985-1990 *Senior Research Assistant*, Southeast Michigan Traumatic Brain Injury Systems (SEMTBIS) and Spinal Cord Injury Research, Department of Psychology, Rehabilitation Institute of Michigan, Detroit, Michigan.

Honors and Professional Memberships

- 2009-Present **American Public Health Association (APHA)**
- 2009-Present **Executive Advisory Board**, Wayne State University School of Medicine, Department of Pulmonary Critical Care & Sleep Medicine: Sleep Neurobiology Respiratory and Epidemiology (SNORE) NIH Institutional Training Program, Detroit, Michigan (NIH Grant Submission: Not Funded)
- 2009-Present **Otsego County Housing Commission**, Gaylord, Michigan
- 2002-2003 **Fellowship/Scholarship, Mid-America Regional Public Health Leadership Institute (MARPHLI)**, University of Illinois at Chicago, School of Public Health

Bibliography—Articles in Refereed Journals:

Warsow KM, Karna K, Morgan W: Bioterrorism Preparedness: Thinking globally acting locally. *Leadership in Public Health* Volume 6 (1), Fall 2002:39-48.

JG Tyburski, Wilson RF, **Warsow KM**, McCreadie Scott: A trial of ciprofloxacin plus metronidazole versus gentamicin plus metronidazole for penetrating abdominal trauma. *Archives of Surgery* 1998; 133: 1289-1296

Wilson RF, Tyburski JG, Kubinec SM, **Warsow KM**, Larky HC, Wilson SR, Schermerhorn T. Intraoperative end-tidal CO₂ levels and derived calculations correlated with outcome in trauma patients. *J Trauma* 41(4): 606-611, 1996.

Wilson RF, Mammen EF, Tyburski JG, **Warsow KM**, Kubinec SM. Antithrombin levels related to infections and outcome. *J Trauma* 40(3):384-387, 1996

Diebel L., Wilson RF, Heins J., Larky H., **Warsow KM**, Wilson S: End diastolic volume vs. PAWP in evaluating preload in ICU trauma patients. *J Trauma* 37: 950-955, 1994.

Published Abstracts:

Warsow KM, Cunningham K, Harris L, Johnson C, Tyler-Jamison, B: The Christmas massacre, a case study (Terrorism), Mid-America Regional Public Health Leadership Institute 2003. www.uic.edu/sph/chs/php/MARPHLI/doc files/All CS Digests.htm

Tyburski JG, Wilson RF, **Warsow KM**, McCreadie S.: A trial of ciprofloxacin plus metronidazole versus gentamicin plus metronidazole for penetrating abdominal trauma. *Surgical Infection Society*, New York City, New York, April 30- May 2, 1998.

Wilson RF, **Warsow KM**, Mammen B, Tyburski JG.: Antithrombin levels in patients with trauma and/or infections. *The Eastern Trauma Association, 25th Annual Scientific Meeting*, Huntly Lodge, Big Sky, Montana, August 13-16, 1995.

Grant Composition:

Transportation Investment **Generating Economic Recovery (TIGER)**, City of Gaylord/Otsego County Road Commission (Local Government), Gaylord, Michigan. USDOT Grant Submission September 15, 2009 (Pending).

Sleep, Neurobiology, Respiration and Epidemiology (SNORE), Department of Medicine Internal, Division of Pulmonary Critical Care and Sleep Medicine, Wayne State University School of Medicine, Detroit, Michigan. Institutional Mentor-Protégé T32 Training Grant, Submitted NIH, January 25, 2009 (Not Funded. Resubmission Planned).

Computer Tomography Incidental Findings in the Trauma Patient. Akron General Medical Center, Department of Surgery, Division of Trauma (In-House Investigator-Initiated Research Study) 2007.

Northeastern Ohio Brain Injury System (NEOBIS): Preliminary Evaluation. Akron General Medical Center, Department of Surgery, Division of Trauma, September 2007.

Risk Factors of Invasive Aspergillus Infection in the Trauma Patient. Akron General Medical Center, Department of Surgery, Division of Trauma, Funded by Merck Pharmaceutical, June 2007.

An Integrative Case Management Approach to Treating the Urban African American Asthmatic. Wayne State University, School of Medicine/Harper Hospital, Department of Medicine, Pulmonary Critical Care (NIH/AHRQ submission 2002).

A Prospective, Randomized, Double-Blind Trial of Ciprofloxacin Plus Metronidazole versus Gentamicin Plus Metronidazole for the Empiric Treatment of Penetrating Abdominal Trauma (IND # 41-551). Funded by Miles/Bayer Pharmaceutical, May 1993.

Thrombate III (Antithrombin III) Replacement Therapy in Trauma Patients with Coagulation Deficiencies. Bayer Pharmaceutical (submitted August 1996, funding was not available by the sponsor).

Grant Awards:

Sub-Investigator. Risk Factors of Invasive Aspergillus Infection in the Trauma Patient. Akron General Medical Center, Department of Surgery, Division of Trauma, Funded by Merck Pharmaceutical, June 2007.

Sub-Investigator. A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200mg PAR-101 q12h With 125mg Vancomycin Taken q6h for Ten Days in Subjects With Clostridium Difficile-Associated Diarrhea. April 2007, Funded by Optimer Pharmaceutical Inc.

Sub-Investigator. A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Evaluation of the Safety and Efficacy of α -hANP Infusion (Carperitide for injection :SUN 4936) in Patients with Acute Respiratory Distress Syndrome

Sub-Investigator. A Randomized, Double-Blind, Comparative Study of the Efficacy and Safety of Synercid Monotherapy Regimens and Synercid in Combination with Ampicillin in the Treatment of Infection Caused by Vancomycin-Resistant Enterococcus faecium (VREF). June 1999, Funded by Rhone-Poulenc Rorer Research and Development.

Sub-Investigator. An Open-Label, Comparative, Randomized, Multicenter Phase III Study of Intravenous Treatment Synercid 7.5mg/kg q 8 hours plus Aztreonam 2g q 8 hours Versus Standard Therapy in the Treatment of 190 Adult Evaluable Hospitalized Patients with Nosocomial Pneumonia due, at least in part, to Gram Positive Cocci. June 1999, Funded by Rhone-Poulenc Rorer Research/Development.

Sub-Investigator. A Multicenter, Randomized, Open-Label Study to Compare the Safety and Efficacy of Levofloxacin with that of Imipenem/Cilastatin in the Treatment of Nosocomial Pneumonia. June 1999, Funded by Ortho-McNeil a Division of R.W. Johnson Research Institute.

Sub-Investigator. A Phase III Study to Determine the Efficacy and Safety for recombinant Human Activated Protein C in Severe Sepsis. April 1999, Funded by Eli Lilly and Company.

Sub-Investigator: Antithrombin III in Patients with Severe Sepsis: A Multinational, Double-Blind, Randomized, Placebo-Controlled Phase III Study. June 1999, Funded by Centeon Clinical Research and Development.

Sub-Investigator: An Open-Label, Randomized, Comparison of the Efficacy, Safety, Treatment Outcomes and Total Cost of I.V. Zosyn to those of I.V. Unasyn plus Gentamicin for the Treatment of Patients with Community Acquired Infections Due to Complicated Appendicitis. June 1997, Funded by Wyeth-Ayerst Laboratories.

Sub-Investigator: Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Bactericidal/Permeability-Increasing Protein (rBPI₂₁) for Treatment of Patients with Hemorrhage Due to Trauma. August 1995, Funded by Xoma Corporation.

Sub-Investigator: A Double-Blind, Multicenter, Comparative Study of Timentin and Primaxin in the Prevention of Infections in Patients with Penetrating Intestinal Injury. June 1994, Funded by SmithKline Beecham Pharmaceutical.

Sub-Investigator: An Open-Label, Randomized, Comparative, Multicenter Study of Clinafloxacin versus a Ceftazidime-Based Regimen in the Treatment of Nosocomial Pneumonia (Protocol 960-012). Funded by Parke-Davis Pharmaceutical, May 1993.

Sub-Investigator: A Double-Blind, Prospective, Randomized, Multicenter Study Comparing Clinafloxacin (CI-960) and Imipenem for the Treatment of Complicated Intra-Abdominal Infections (Protocol 960-013). Funded by Parke-Davis Pharmaceutical, May 1993.